Reply

We appreciate the interest shown by Drs Jonna and Kim in our work. The main aim of our study was to evaluate the clinical benefit of prophylactic use of nepafenac 0.3% once daily in reducing the risk of postoperative macular edema (ME) after cataract surgery in patients with nonproliferative diabetic retinopathy. It is a known fact that even though the magnitude of postoperative ME is high, in most cases ME is self-limiting and not associated with impaired vision. However, it cannot be determined in which patients postoperative ME will lead to significant loss of visual acuity (VA).

Source: Ophthalmology - December 18, 2017 Category: Opthalmology Authors: Rishi P. Singh, Robert Lehmann, Joseph Martel, Kevin Jong, Ayala Pollack, Alexis Tsorbatzoglou, Giovanni Staurenghi, Guadalupe Cervantes-Coste Cervantes, Louis Alpern, Satish Modi, Liza Svoboda, Adeniyi Adewale, Glenn J. Jaffe Tags: Correspondence Source Type: research